WO2005021704A3 - In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders - Google Patents

In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders Download PDF

Info

Publication number
WO2005021704A3
WO2005021704A3 PCT/IB2004/002847 IB2004002847W WO2005021704A3 WO 2005021704 A3 WO2005021704 A3 WO 2005021704A3 IB 2004002847 W IB2004002847 W IB 2004002847W WO 2005021704 A3 WO2005021704 A3 WO 2005021704A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
stem cells
gabaergic neurons
embryonic stem
treatment
Prior art date
Application number
PCT/IB2004/002847
Other languages
French (fr)
Other versions
WO2005021704A2 (en
Inventor
Firdos Alam Khan
Satish Mahadeorao Totey
Original Assignee
Reliance Life Sciences Pvt Ltd
Firdos Alam Khan
Satish Mahadeorao Totey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliance Life Sciences Pvt Ltd, Firdos Alam Khan, Satish Mahadeorao Totey filed Critical Reliance Life Sciences Pvt Ltd
Priority to CA002537403A priority Critical patent/CA2537403A1/en
Priority to JP2006525210A priority patent/JP2007520207A/en
Priority to EP04769254A priority patent/EP1660627A4/en
Priority to KR1020067004487A priority patent/KR101254554B1/en
Priority to BRPI0413406-0A priority patent/BRPI0413406A/en
Priority to AU2004268177A priority patent/AU2004268177B2/en
Publication of WO2005021704A2 publication Critical patent/WO2005021704A2/en
Priority to IL173889A priority patent/IL173889A/en
Publication of WO2005021704A3 publication Critical patent/WO2005021704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as GABAergic neurons from pluripotent stem cells, for example embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of GABAergic neurons have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurodegenerative disorders and neuronal diseases such as stroke, ischemia, epilepsy, and Huntington's disease.
PCT/IB2004/002847 2003-09-03 2004-09-02 In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders WO2005021704A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002537403A CA2537403A1 (en) 2003-09-03 2004-09-02 In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders
JP2006525210A JP2007520207A (en) 2003-09-03 2004-09-02 In vitro generation of GABAergic neurons derived from embryonic stem cells and their use in the treatment of neurological diseases
EP04769254A EP1660627A4 (en) 2003-09-03 2004-09-02 In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders
KR1020067004487A KR101254554B1 (en) 2003-09-03 2004-09-02 In Vitro Generation of GABAergic Neurons from Embryonic Stem Cells and Their Use in the Treatment of Neurological Disorders
BRPI0413406-0A BRPI0413406A (en) 2003-09-03 2004-09-02 in vitro generation of embryonic stem cell GABAergic neurons and their use in the treatment of neurological disorders
AU2004268177A AU2004268177B2 (en) 2003-09-03 2004-09-02 In vitro generation of GABAergic neurons from embryonic stem cells and their use in the treatment of neurological disorders
IL173889A IL173889A (en) 2003-09-03 2006-02-23 In vitro enriched population of gabaergic neurons for use in cell therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN901MU2003 2003-09-03
IN901/MUM/2003 2003-09-03
US55789504P 2004-03-31 2004-03-31
US60/557,895 2004-03-31

Publications (2)

Publication Number Publication Date
WO2005021704A2 WO2005021704A2 (en) 2005-03-10
WO2005021704A3 true WO2005021704A3 (en) 2006-08-10

Family

ID=34276872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002847 WO2005021704A2 (en) 2003-09-03 2004-09-02 In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders

Country Status (10)

Country Link
US (1) US7820439B2 (en)
EP (1) EP1660627A4 (en)
JP (1) JP2007520207A (en)
KR (1) KR101254554B1 (en)
AU (1) AU2004268177B2 (en)
BR (1) BRPI0413406A (en)
CA (1) CA2537403A1 (en)
IL (1) IL173889A (en)
RU (1) RU2380410C2 (en)
WO (1) WO2005021704A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005014537D1 (en) * 2005-03-23 2009-07-02 Stiftung Caesar Neural stem cells
CN101180389A (en) * 2005-05-17 2008-05-14 利莱恩斯生命科学有限公司 Establishment of a human embryonic stem cell line using mammalian cells
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101410509B (en) * 2006-02-23 2016-05-18 维亚赛特公司 For cultivate can noble cells composition and method
EP2314671B1 (en) 2008-06-06 2022-08-03 Riken Method for culture of stem cell
US20130022989A1 (en) * 2009-06-25 2013-01-24 The Trustees Of Columbia University In The City Of New York Dental stem cell reprogramming
US10793830B2 (en) 2009-11-05 2020-10-06 Riken Method for producing retinal tissue in vitro
RU2431666C1 (en) * 2010-04-06 2011-10-20 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Method for producing neuronal matrix
KR101346582B1 (en) * 2011-11-08 2013-12-30 서울대학교산학협력단 A pharmaceutical composition for treating neuropathic pain comprising GABAergic neurons, which is adipose tissue-derived stem cell(ATSCs) differentiated by CBM-1078 as active ingredients
CA3143449A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
EP3183338B1 (en) 2014-08-19 2020-03-04 FUJIFILM Cellular Dynamics, Inc. Neural networks formed from cells derived from pluripotent stem cells
SG11201707857VA (en) * 2015-03-30 2017-10-30 Ajinomoto Kk Chelated iron-containing culture medium for neural stem cells
CN108291207A (en) 2015-10-08 2018-07-17 神经元治疗公司 Neural precursor group and application thereof
US10973930B2 (en) 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
US20210363483A1 (en) * 2017-11-10 2021-11-25 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
RU2690498C1 (en) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Method for preparing a nootropic composition based on polypeptide complexes isolated from neurons and glial cells obtained by directional differentiation of induced human pluripotent stem cells
WO2023039567A2 (en) 2021-09-10 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
CA3235390A1 (en) 2021-10-29 2023-05-04 Deepika Rajesh Dopaminergic neurons comprising mutations and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092012A1 (en) * 2001-03-30 2004-05-13 Hideyuki Okano Process for producing nerve stem cells, motor neurons, and gabaergic neurons from embryonic stem cells
US20050221479A1 (en) * 2002-06-24 2005-10-06 Tanabe Seiyaku Co., Ltd. Process for producing nerve cells
US20060014280A1 (en) * 2002-09-25 2006-01-19 Condie Brian G Compositions and methods for enrichment of neural stem cells using ceramide analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106327A (en) 1992-07-21 1997-06-10 Perini Fabio Spa Machine and method for the formation of coreless rolls of web material
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5514552A (en) 1993-04-30 1996-05-07 Arch Development Corporation Hybrid neuronal cell lines compositions and methods
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JP2001508302A (en) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド Embryonic stem cell serum replacement
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
CA2307807C (en) 1997-10-23 2008-09-02 Andrea G. Bodnar Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US20020168766A1 (en) 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
WO2001083715A2 (en) 2000-05-01 2001-11-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary, Derivation of midbrain dopaminergic neurons from embryonic stem cells
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
US20020009743A1 (en) 2000-05-17 2002-01-24 Carpenter Melissa K. Neural progenitor cell populations
US6602680B2 (en) 2000-07-14 2003-08-05 The Regents Of The University Of California Production of gabaergic cells
US20030036195A1 (en) 2001-04-20 2003-02-20 Lorenz Studer Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
BR0212098A (en) 2001-08-23 2004-08-03 Reliance Life Sciences Pvt Ltd Internal cell mass isolation method for the establishment of human embryonic stem cell lines (hesc)
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
CA2488429C (en) 2002-06-05 2013-05-07 Benjamin Eithan Reubinoff Generation of neural stem cells from undifferentiated human embryonic stem cells
US7390659B2 (en) 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
WO2004015077A2 (en) 2002-08-08 2004-02-19 University Of Georgia Research Foundation, Inc. Compositions and methods for neural differentiation of embryonic stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092012A1 (en) * 2001-03-30 2004-05-13 Hideyuki Okano Process for producing nerve stem cells, motor neurons, and gabaergic neurons from embryonic stem cells
US20050221479A1 (en) * 2002-06-24 2005-10-06 Tanabe Seiyaku Co., Ltd. Process for producing nerve cells
US20060014280A1 (en) * 2002-09-25 2006-01-19 Condie Brian G Compositions and methods for enrichment of neural stem cells using ceramide analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROY N.S. ET AL.: "In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus", NATURE MEDICINE, vol. 6, March 2000 (2000-03-01), pages 271 - 277, XP000992689 *

Also Published As

Publication number Publication date
WO2005021704A2 (en) 2005-03-10
US7820439B2 (en) 2010-10-26
JP2007520207A (en) 2007-07-26
KR101254554B1 (en) 2013-04-22
AU2004268177B2 (en) 2010-02-25
IL173889A0 (en) 2006-07-05
KR20060091296A (en) 2006-08-18
RU2006110203A (en) 2007-10-10
CA2537403A1 (en) 2005-03-10
EP1660627A2 (en) 2006-05-31
BRPI0413406A (en) 2006-10-17
US20050095702A1 (en) 2005-05-05
EP1660627A4 (en) 2009-04-15
AU2004268177A1 (en) 2005-03-10
IL173889A (en) 2011-11-30
RU2380410C2 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
WO2005021704A3 (en) In vitro generation of gabaergic neurons from embryonic stem cells and their use in the treatment of neurological disorders
WO2004081172A3 (en) Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
Zietlow et al. Human stem cells for CNS repair
Nandoe Tewarie et al. Stem cell-based therapies for spinal cord injury
GB2452667A (en) Efficient generation of neural progenitors, neurons and dopaminergic neurons from human embryonic stem cells
EP1561814A4 (en) Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
Wislet-Gendebien et al. Adult bone marrow: which stem cells for cellular therapy protocols in neurodegenerative disorders?
GB2407821A (en) Generation of neural stem cells from undifferentiated human embryonic stem cells
MY159562A (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
Wang et al. Stem cell transplantation: a promising therapy for Parkinson’s disease
WO2005017131A3 (en) Methods for the differentiation of human stem cells
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
ATE330001T1 (en) THERAPEUTIC USE OF MESENCHYMAL CURRENT CELLS
AR044692A1 (en) METHODS TO PRODUCE NEURONS
EP1712638A4 (en) MARKER Lmx1a SPECIFIC TO DOPAMINE-PRODUCING NEURON
Srivastava et al. Potentials of ES cell therapy in neurodegenerative diseases
GB2427876A (en) Methods for generating neuronal cells from human embryonic stem cells and uses thereof
KR20160024126A (en) Process for preparing astrocyte
Ibekwe et al. Potential roles of stem cells in the management of sensorineural hearing loss
Gottlieb et al. Reply to “What is a functional recovery after spinal cord injury?”
WO2022150541A8 (en) Methods of generating cortical excitatory neurons
AU2020397893A8 (en) Regulatory T cell (Treg) compositions and methods for treating neurodegenerative disease
Gandhi et al. Stem cell therapy for Parkinson’s disease: a review
WO2010110602A3 (en) Method for regenerating dopaminergic neurons in the substantia nigra pars compacta using human adult stem cells or precursor cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480025337.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 173889

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2537403

Country of ref document: CA

Ref document number: 2004268177

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006525210

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020067004487

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004769254

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004268177

Country of ref document: AU

Date of ref document: 20040902

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006/02498

Country of ref document: ZA

Ref document number: 200602498

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006110203

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004769254

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 1020067004487

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0413406

Country of ref document: BR